From: Expression of Cyr61 is associated with clinical course in patients with Crohn’s disease
Patients without clinical recurrence (n = 54) | Patients with clinical recurrence (n = 29) | P value | |
---|---|---|---|
Age, years., (mean ± SD) | 31.6 ± 11.1 | 28.4 ± 9.9 | 0.21 |
Male, n (%) | 40 (74.1%) | 22 (75.9%) | 0.86 |
Disease duration, years, median (range) | 4.0 (0.0 ~ 15.0) | 3.0 (0.0 ~ 12.0) | 0.06a |
Location of disease (Montreal classification), n (%) | 0.54 | ||
Ileum (L1) | 4 (7.4%) | 2 (6.9%) | |
Colon (L2) | 2 (3.7%) | 1 (3.4%) | |
Ileocolon (L3) | 48 (88.9%) | 24 (82.8%) | |
Concomitant UGI disease (L4) | 0 (0.0%) | 2 (6.9%) | |
Medication at the time of colonoscopy, n (%) | |||
5-ASA | 42 (77.8%) | 19 (65.5%) | 0.23 |
Systematic steroid | 0 (0.0%) | 2 (6.9%) | 0.12b |
Azathioprine/6-mercaptopurine | 19 (35.2%) | 5 (17.2%) | 0.09 |
TNF-α antagonist | 4 (7.4%) | 3 (10.3%) | 0.70b |
CDAI, median (range) | 100 (2–328) | 171 (41–470) | < 0.01a |
CDEIS, median (range) | 4.0 (0.25–31.5) | 4.0 (0.25–31.0) | 0.50a |
SES-CD, median (range) | 5.0 (1.0–36.0) | 5 (1–27) | 0.33a |